• Nie Znaleziono Wyników

Correction: Non–vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis

N/A
N/A
Info
Pobierz
Protected

Academic year: 2022

Share "Correction: Non–vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis"

Copied!
1
0
0

Ładowanie.... (Zobacz pełny tekst teraz)

Pobierz teraz ( 1 Stron )

Pełen tekst

(1)

1

In the Expert Opinion and Position Paper entitled “Non ‑vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis” published in the April 2019 issue (Witkowski A, Barylski M, Filipiak KJ, et al. Kardiol Pol. 2019; 77: 490‑504. doi:10.5603/KP.a2019.0033), there were errors in FIGURE 1 on page 492. The legend at the bottom of the figure should list “Vitamin K antagonist” first, followed by “Factor Xa inhibitor” and “Direct thrombin inhibitor” below. In the figure, under the “Intrinsic coagulation pathway”, factors “XII”, “XI”, and “IX” on the right ‑hand side should read “XIIa”, “XIa”, and

“IXa”, and under the “Extrinsic coagulation pathway”, factor “VII” on the left‑hand side should read “VIIa.”

The same changes apply to the Polish version of the article in Supplementary material online.

The article is correct at www.mp.pl/kardiologiapolska.

The corrected figure is attached below.

C O R R E C T I O N S

Direct thrombin inhibitor Intrinsic coagulation

pathway

XII XIIa

XI

IX

VIII

X

V

Vitamin K antagonist Factor Xa inhibitor

Va

II IIa

Fibrinogen Fibrin

IXa

VIII

Xa

VIIa VII

XIa

Extrinsic coagulation pathway

Tissue factor

Cytaty

Pobierz teraz ( PDF - 1 Stron - 95.09 KB )

Powiązane dokumenty

Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency

Results: Based on many polemical discussions, including post-conference networking, the key opinion leaders established ranges of serum 25-hydroxyVitamin D concentration

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

To improve the safety of anticoagulation in the era of non–vitamin K antagonist oral anticoagulants (NOACs, or direct oral anticoagulants [DOACs], including dabigatran,

Efficacy and safety of non–vitamin K antagonist oral anticoagulants in very elderly patients with atrial fibrillation: a single-center experience

‑dose dabigatran should be used in patients older than 80 years, while apixaban, 2.5 mg twice daily, is recommended in the presence of creatinine levels of 133  μ mol/l or higher or

Non–vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and colorectal cancer: a single‑center experience

9 Our study showed that the use of NOACs was not associated with high risk of gastrointestinal bleeds, at least in patients with colorectal cancer after surgery and the first

Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, acetylsalicylic acid; BMS, bare metal stent; CABG, coronary artery bypass grafting; CrCl,

How can we reverse bleeding in patients on direct oral anticoagulants?

The direct oral anticoagulants (DOACs), or non-vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, which inhibits thrombin, as well as rivaroxaban,

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic re- view

Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation

In conclusion: 1) Standard doses of NOACs were pre- scribed to most hospitalised AF patients; 2) Apixaban was prescribed more frequently in the reduced-dose regimen,